Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in japanese patients with non-small cell lung cancer: The okayama lung cancer study group experience

Katsuyuki Hotta, Katsuyuki Kiura, Nagio Takigawa, Hiroshige Yoshioka, Shingo Harita, Shoichi Kuyama, Toshiro Yonei, Keiichi Fujiwara, Tadashi Maeda, Keisuke Aoe, Hiroshi Ueoka, Haruhito Kamei, Shigeki Umemura, Tomonori Moritaka, Yoshihiko Segawa, Haruyuki Kawai, Akihiro Bessho, Katsuya Kato, Masahiro Tabata, Mitsune Tanimoto

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

BACKGROUND:: Data comparing the incidence and pattern of interstitial lung disease (ILD) in non-small cell lung cancer patients receiving treatment with gefitinib versus erlotinib, both of which are epidermal growth factor receptor tyrosine kinase inhibitors, are scarce. We investigated the incidence of ILD in Japanese patients treated with gefitinib or erlotinib. METHODS:: We reviewed the clinical records of 209 patients treated with erlotinib in 2008 (cohort A) and 330 treated with gefitinib between 2000 and 2003 (cohort B). Toxicity within the first month of treatment was investigated. RESULTS:: The patients in cohort A had fewer known risk factors for ILD (e.g., poor performance status and prior pulmonary fibrosis). ILD was detected in two patients (1.0%) from cohort A and eight patients (2.4%) from cohort B during the first month of treatment. The events were graded as follows: one patient each in grades 1 and 2 (cohort A), and one, one, and six patients in grades 3, 4, and 5, respectively (cohort B). Multivariate analysis revealed that poor performance status and prior pulmonary fibrosis were significantly correlated with the occurrence of ILD, but the type of epidermal growth factor receptor tyrosine kinase inhibitor administered was not. CONCLUSION:: There was a somewhat lower incidence of ILD with erlotinib therapy than with gefitinib therapy, despite no statistically significant difference. Patient selection based on awareness by Japanese physicians of the risk factors for ILD, rather than the type of agent, may explain the difference in ILD incidence between the two treatments.

Original languageEnglish
Pages (from-to)179-184
Number of pages6
JournalJournal of Thoracic Oncology
Volume5
Issue number2
DOIs
Publication statusPublished - Feb 2010

Keywords

  • EGFR tyrosine kinase inhibitors
  • Interstitial lung disease
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in japanese patients with non-small cell lung cancer: The okayama lung cancer study group experience'. Together they form a unique fingerprint.

  • Cite this

    Hotta, K., Kiura, K., Takigawa, N., Yoshioka, H., Harita, S., Kuyama, S., Yonei, T., Fujiwara, K., Maeda, T., Aoe, K., Ueoka, H., Kamei, H., Umemura, S., Moritaka, T., Segawa, Y., Kawai, H., Bessho, A., Kato, K., Tabata, M., & Tanimoto, M. (2010). Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in japanese patients with non-small cell lung cancer: The okayama lung cancer study group experience. Journal of Thoracic Oncology, 5(2), 179-184. https://doi.org/10.1097/JTO.0b013e3181ca12e0